|Day's range||3.0000 - 3.0000|
The stock market is in a precarious place. The sharp rise in both interest rates and bond yields has weighed heavily on most stocks since the first quarter of 2022. The top-shelf drugmakers Novartis (NYSE: NVS) and Vertex Pharmaceuticals (NASDAQ: VRTX) are two prime examples.
Vertex Pharmaceuticals (NASDAQ: VRTX) may not be a household name like some healthcare companies, but this is a business that investors may be hard-pressed to overlook, bull or bear market. Vertex has a long history of profitability and revenue growth, and amassed earnings of $3.3 billion in 2022 alone. The life expectancy for cystic fibrosis patients has improved dramatically over the past few decades.
While no one can predict when the next prolonged bull move will appear, the stock market has proven time and again its ability to rebound from even the most dire periods of volatility. Vertex Pharmaceuticals (NASDAQ: VRTX) has continued to deliver gains against the backdrop of the broader volatile market over the last year, but this isn't only a testament to the typical resilience of the healthcare industry in times of economic turmoil. The company continues to rake in revenue, profits, and cash from its portfolio of cystic fibrosis medicines -- currently the only drugs on the market that target the underlying root causes of the genetic ailment.